期刊
JOURNAL OF NUCLEAR MEDICINE
卷 50, 期 -, 页码 106S-121S出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.057281
关键词
PET; therapy monitoring; hypoxia; steroid receptors; proliferation
资金
- National Cancer Institute [R25-CA96945]
This review article discusses PET agents, other than F-18-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-F-18-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-F-18-fluoro-3'-deoxythymidine and F-18-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as Cu-60/62/64-labeled diacetyl-bis(N-4-methylthiosemicarbazone) and F-18-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl-C-11]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16 beta-F-18-fluoro-5 alpha-dihydrotestosterone and 16 alpha-F-18-fluoro-17 beta-estradiol, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据